Gentulizumab in Patients With Advanced Solid Malignancies and Non-Hodgkin Lymphoma
Status:
Recruiting
Trial end date:
2024-05-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and tolerability of gentulizumab, an
anti-CD47 Monoclonal Antibody, in participants with solid tumors and non-Hodgkin lymphoma.